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Management of spontaneous dissection of the cervical carotid
artery
Abstract
This manuscript reviews the management of patients with spontaneous dissection of the cervical internal
carotid artery (sICAD). Recommendations are not based on controlled-randomized trials, but on
case-control and observational, hospital-based studies, and case reports. Vascular risk factors seem to be
as prevalent in patients with sICAD as in age-matched, healthy volunteers. Stroke prevention includes
the treatment of vascular risk factors and the administration of oral aspirin, which may be as effective as
anticoagulation. The few available data indicate that most patients with sICAD causing severe stenosis
or occlusion, or an aneurysm can be treated conservatively. Patients with sICAD were not excluded in
the intravenous controlled-randomized thrombolysis trials with tissue plasminogen activator, but were
excluded in the intraarterial controlled-randomized thrombolysis trials. Taking the few published case
series and reports on thrombolysis in patients with sICAD into consideration, intravenous thrombolysis
may be beneficial, whereas it remains unclear whether intraarterial thrombolysis is useful.
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This manuscript reviews the management of patients with spontaneous dissection of the cervical 
internal carotid artery (sICAD). The first part will deal with stroke prevention, in particular the 
vascular risk factors, antithrombotic therapy, and the treatment of severe stenosis or occlusion, 
and dissecting aneurysm. The second part will discuss thrombolytic treatment of acute ischemic 
stroke due to sICAD. 
 
 
1  Stroke Prevention 
1.1 Vascular risk factors 
Arterial hypertension is the main independent risk factor for aortic dissection, and sudden, 
brief blood pressure changes are steeper in hypertensive compared to normotensive subjects 
(Mancia et al 2003). It is thus fair to assume that it may also be involved in the pathogenesis of 
sICAD (Baumgartner 2008). Two case-control studies in patients with spontaneous cervical 
artery dissection (sCAD) found no correlation between hypertension and sCAD (Arnold et al 
2009; Pezzini et al 2006). In a French case-control study, major vascular risk factors, body 
weight, body height and body mass index (BMI) of 239 patients obtained from a prospective 
hospital-based sCAD registry were compared with 516 age- and sex-matched healthy controls 
(Arnold et al 2009). The overall frequency of hypertension did not differ between sCAD patients 
and controls (Arnold et al 2009). An Italian case-control study compared the prevalence of 
hypertension in 153 consecutive patients with sCAD and 153 controls (Pezzini et al 2006). 
Again, the frequency of hypertension did not differ between the two groups. Both case-control 
studies showed a similar frequency of hypertension for men and women (Arnold et al 2009; 
Pezzini et al 2006). In contrast, men had more often a history of hypertension than women (31% 
vs. 15%; p<0.0001) in an observation study examining gender differences in 696 Swiss and 
French patients with sCAD (Arnold et al 2006).  
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In the Italian case-control study mentioned above hypertension was associated with brain 
infarction caused by sCAD (odds ratio (OR), 1.94; 95% confidence interval (CI), 1.01 to 3.70; p 
= 0.045), particularly when the ischemic lesion resulted from spontaneous vertebral artery 
dissection (OR, 2.69; 95% CI, 1.20 to 6.04; p = 0.017) (Pezzini et al 2006). 
Diabetes mellitus, current and former smoking. The overall frequency of diabetes (patients: 
1% of 236 cases; controls: 1% of 508 cases), current smoking (patients: 27% of 238 cases; 
controls: 31% of 516 cases) and past smoking (patients: 17% of 238 cases; controls: 19% of 516 
cases) did not differ between sCAD patients and controls in the aforementioned French case-
control study, and gender specific subgroup analyses showed similar results for both sexes 
(Arnold et al 2009). 
Hypercholesterolemia. In the French case-control study mentioned above the frequency of 
hypercholesterolemia (patients: 68% of 178 cases; controls: 64% of 515 cases) and mean total 
plasma cholesterol level (patients and controls: 5.5 ± 1.1 mmol/L) did not differ between the two 
groups (Arnold et al 2009). The frequency of hypercholesterolemia was lower in Swiss and 
French sCAD patients and normal subjects: It was 53% in 301 patients with sCAD (Arnold et al 
2006), and about 60% in the Swiss MONICA center Vaud/Fribourg (Marti et al 1990), Swiss 
military personnel (Keller 1990) and 61'108 French subjects over 15 years of age who 
volunteered for a systematic medical check-up (Marques-Vidal et al 2004). These data suggest 
that the frequency of hypercholesterolemia might be similar in sCAD patients and control 
subjects. 
An observational study found that hypercholesterolemia occured more often in sICAD that 
caused ischemic events compared to those sICAD that caused just local symptoms and signs on 
the side of dissection (head- and neck pain, pulsatile tinnitus, Horner syndrome or cranial nerve 
palsy) or remained clinically asymptomatic (Baumgartner et al 2001). 
Homocysteine. Case-control and observational studies suggest that patients with sCAD have a 
mild elevation of total homocysteine (tHcy) levels, an increased prevalence of 
 3
hyperhomocysteinemia, or both (Benninger et al 2009; Gallai et al 2001; Konrad et al 2004; 
Pezzini et al 2002). The tHcy levels in patients with sCAD (± ischemic stroke) are lower 
compared to those in patients with ischemic stroke not due to sCAD (Benninger et al 2009; 
Kelly et al 2002; Pezzini et al 2002; Soriente et al 1998). Hyperhomocysteinemia damages the 
endothelium according to in vitro and animal studies (Harker et al 1976; Harker et al 1974; Wall 
et al 1980), impairs endothelial-dependent and flow mediated vasodilation in humans (Woo et al 
1997), and is associated with premature peripheral and cerebrovascular disease and 
atherosclerosis in case-control studies (Boers et al 1985; Clarke et al 1991). Gallai et al (Gallai 
et al 2001) have suggested that tHcy levels slightly above normal predispose to the development 
of an intimal tear and sCAD without the occurrence of atherosclerosis, although the underlying 
mechanism remains elusive. Several arguments suggest that the small difference in tHcy levels 
between normals and patients with sCAD might be an artifact (Benninger et al 2009): (1) tHcy 
levels are not assessed before, but after the onset of stroke. Even though the tHcy samples are 
collected soon after the ischemic event, there is still time for them to be affected by the stroke. 
(2) Homocysteine is assumed to be an acute-phase reactant (Brattstrom & Wilcken 2000; 
Christen et al 2000). Therefore, elevated tHcy could be the consequence of cerebral ischemia or 
also an infection which has been shown to be associated with sCAD (Grau et al 1999; Guillon et 
al 1998) rather than a cause of the disease. Also, food deprivation increases the tHcy levels 
(Lindgren et al 1995; Nurk et al 2001). In acute stroke, patients are kept fasting, and tHcy may 
therefore increase independently of the ischemic process (Benninger et al 2009). 
In conclusion, hypertension might be a risk factor for sCAD causing ischemic brain infarction 
and sCAD in men. Mild hyperhomocysteinemia was found to be more prevalent in sCAD 
patients, although it is not clear whether this slight increase of the tHcy level is a risk factor for 
dissection or an artifact. The other vascular risk factors cigarette smoking, diabetes mellitus and 
hypercholesterolemia seem to be similarly frequent in patients with sCAD and healthy 
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volunteers. These findings suggest that the vascular risk factors should also be assessed in 
patients with sCAD. 
 
1.2 Body height, body weight, and body mass index 
A French case-control study reported that (1) mean body height was higher in sCAD patients 
than in controls (171.3 ± 8.6 cm vs. 167.7 ± 8.9 cm, p<0.0001), (2) sCAD patients had a lower 
mean body weight than controls (67.5 ± 12.2 kg vs. 69.3 ± 14.6) kg; p<0.001), and (3) sCAD 
patients had a lower mean body mass index (22.9 ± 3.3 kg/m² vs. 24.5 ± 4.2 kg/m²; p<0.0001) 
than controls (Arnold et al 2009). This association was observed in both genders. Compared to 
healthy controls, the taller patients with sCAD might have a greater radius from the axis of neck 
rotation, the cervical spinal column, to the point of application of the force causing the intimal 
tear in the carotid artery. Consequently, the lever arm and the ensuing torque affecting the 
cervical ICA during neck movements might be greater in sCAD patients compared to normals. 
However, there are no data to prove this hypothesis, because the corresponding anatomical data 
were not measured. Genetic factors such as the increased frequency of connective tissue 
abnormalities in taller subjects might be another explanation. E. g., patients with Marfan’s 
syndrome are known to be taller than the normal population (Erkula et al 2002). However, just 
two of 696 sCAD patients reported in the largest yet published series (Arnold et al 2006) 
suffered from this connective tissue disorder. 
 
1.3 Antithrombotic treatment 
Brain imaging studies performed in patients with sICAD suggest that the essential mechanism 
of stroke is cerebral embolism (Benninger et al 2004). These findings are underscored by 
transcranial Doppler sonography investigations, which reported microembolic signals in middle 
cerebral arteries that were irrigated by dissected carotids (Srinivasan et al 1996). These findings 
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suggest that antithrombotic treatment for preventing embolic stroke is the key issue in patients 
with sICAD. 
No controlled randomized or non-controlled study has compared the safety and efficacy of an 
antithrombotic treatment with placebo or different antithrombotic treatments (e. g. aspirin with 
anticoagulation) in patients with sICAD (Lyrer & Engelter 2004). A systematic meta-analysis 
investigated in patients with sICAD, whether the outcomes “death from all causes” and “dead or 
disabled” differs after treatment with antiplatelet agents or anticoagulation (Lyrer & Engelter 
2004). There was no difference for the outcome "death of all causes" as 2% of 109 patients 
treated with antiplatelets and 2% of 218 patients treated with anticoagulation died. The endpoint 
"dead or disabled" did not differ between both groups (antiplatelet treatment: 24% of 59 
patients; anticoagulation: 14% of 119 patients; Peto OR, 1.94; 95%-CI, 0.76-4.91).  
In a recent study, prospectively collected data from 298 consecutive patients with sICAD treated 
with anticoagulants alone (n=202) or aspirin alone (n=96) was retrospectively analyzed 
(Georgiadis et al 2009). Admission diagnosis was ischemic stroke in 165, transient ischemic 
attack (TIA) in 37, retinal ischemia in 8 and local symptoms and signs in 80 patients, while 8 
patients were asymptomatic. Clinical follow-up was obtained after 3 months by neurological 
examination (97% of patients) or structured telephone interview. Outcome measures were (1) 
new cerebral ischemic events, defined as ischemic stroke, TIA or retinal ischemia, (2) 
symptomatic intracranial hemorrhage and (3) major extracranial bleeding. During follow-up, 
ischemic events were rare (ischemic stroke, 0.3%; TIA, 3.4%; retinal ischemia 1%); their 
frequency did not significantly differ between patients treated with anticoagulants (5.9%) and 
those treated with aspirin (2.1%). Same was true for hemorrhagic adverse events 
(anticoagulants, 2%; aspirin, 1%). These data suggest that (1) the frequency of new cerebral and 
retinal ischemic events in patients with sICAD is low and probably independent of the type of 
antithrombotic treatment (aspirin or anticoagulants), and (2) a randomized controlled trial 
comparing aspirin with anticoagulation is needed. 
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Complete recanalisation of a narrowed or occluded sICAD has been recently shown to occur 
mainly in the first 6 months after the onset of symptoms (Nedeltchev et al 2009). These findings 
indicate that antithrombotic treatment is mandatory during this 6 months period.  
The long-term stroke risk of sCAD patients is low and ranges between 0.3 to 1.4% per year in 
French and Swiss series observing 92 to 459 patients during a mean follow-up of 2.6-6.7 years 
(Kremer et al 2003; Leys et al 1995; Touzé et al 2003). There is no study which analyzed 
whether specific subgroups have a higher long-term stroke risk and might benefit from long-
term antithrombotic treatment. It is thus unclear whether patients with sCAD should undergo 
chronic antiplatelet treatment. Patients with persistent aneurysms after sCAD are usually treated 
with aspirin to prevent the development of thrombo-embolism, although no study has evaluated 
whether this treatment is beneficial. 
 
1.4 Treatment of sICAD causing severe stenosis or occlusion 
The rate of ischemic events and intracranial hemorrhage was investigated in patients with 
persistent (n=46) and transient (n=46) severe stenosis or occlusion of the ICA due to unilateral 
sICAD in a non-controlled, long-term observational study (Kremer et al 2003). Patients with 
transient carotid obstruction had a similar length of follow-up (7.2 ± 4.3 years) compared to 
patients with permanent carotid obstruction (6.2 ± 3.4 years). Antithrombotic treatment was 
similar in both groups, though it was administered at the discretion of the treating physician. 
Patients with permanent carotid obstruction showed annual rates of 0.7% for ipsilateral carotid 
territory stroke and of 1.4% for any stroke, whereas patients with transient carotid obstruction 
showed annual rates of 0.3% for ipsilateral carotid territory stroke and of 0.6% for any stroke. 
These results indicate that sICAD has a benign long-term prognosis with low rates of ipsilateral 
carotid territory and any stroke, and that the stroke rate in sICAD is not related to the persistence 
of severe carotid stenosis or occlusion. Accordingly, conservative treatment with antithrombotic 
agents is sufficient in most patients with sICAD causing severe stenosis or occlusion. 
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 1.5 Treatment of dissecting aneurysm 
Three monocenter, non randomized observational studies evaluated the clinical and radiological 
course of cervical aneurysms caused by sICAD during mean follow-up periods ranging from 3 
to 6.5 years (Benninger et al 2007; Guillon et al 1999; Touzé et al 2001). Both studies included 
82 patients with 91 aneurysms of the cervical ICA. Antithrombotic treatment included mainly 
aspirin, a few patients were anticoagulated or had no antithrombotic therapy. During follow-up, 
aneurysms persisted in 64-100% with a decreasing size in 15-30%, whereas the remaining 
aneurysms resolved completely (Benninger et al 2007; Guillon et al 1999; Touzé et al 2001). 
Long-term outcome of cervical aneurysm due to sICAD - regardless of location, size, and 
morphology – seems is benign under conservative treatment including mainly aspirin, as no 
aneurysm ruptured or caused ischemia or new local symptoms or signs (Benninger et al 2007; 
Guillon et al 1999; Touzé et al 2001). These findings suggest that conservative management is 
the treatment of choice in most patients with cervical aneurysms caused by sICAD (Benninger 
et al 2007; Guillon et al 1999; Touzé et al 2001).  
 
 
2  Treatment of Acute Ischemic Stroke 
No controlled randomized trial has investigated the safety and efficacy of intravenous (IVT), 
intraarterial (IAT) or mechanical (MT) thrombolysis in acute ischemic stroke caused by sICAD 
(Georgiadis & Baumgartner 2005). Therefore, all currently available data on this issue are 
derived from observational studies or case reports.  
 
1. Intravenous thrombolysis 
Patients with ischemic stroke caused by sICAD were not excluded in any controlled, 
randomized IVT trial, which evaluated the effect of tissue plasminogen activator (Albers et al 
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2002; Clark et al 1999; Hacke et al 1995; The National Institute of Neurological Disorders and 
Stroke rt-PA Study Group 1995). SICAD is characterized by a false lumen containing the 
intramural hematoma and an intraluminal thrombus. An extension of the mural hematoma may 
cause local signs on the side of dissection or progression of luminal narrowing. Other potential 
complications include the development of an aneurysm, carotid rupture causing cervical or 
subarachnoid hemorrhage (SAH), and arterio-arterial embolism. Georgiadis et al (Georgiadis & 
Baumgartner 2005) summarized four studies reporting on 50 patients with sICAD causing 
ischemic stroke treated with IVT (Derex et al 2000; Georgiadis et al 2005; Rudolf et al 1999). 
No new or worsened local signs, rupture of the dissected artery or SAH were observed (Derex et 
al 2000; Georgiadis et al 2005; Rudolf et al 1999). One patient deteriorated during IVT, possibly 
due to recurrent thromboembolism (Georgiadis et al 2005). Mortality was 8%, and a good 
outcome defined by a modified Rankin scale score of 0-2 points occurred in 40% of patients. 
These data reveal that IVT in ischemic stroke due to sICAD is probably safe. 
 
2.2 Intraarterial and mechanical thrombolysis 
Arterial dissection was an exclusion criterion in all controlled, randomized trials, which 
evaluated the effect of IAT in acute ischemic stroke (Del Zoppo et al 1998; Furlan et al 1999; 
Ogawa et al 2007). In contrast, patients with sICAD were not excluded from the mechanical 
embolus removal in cerebral ischemia (MERCI) trial (Smith et al 2005).  
The potential adverse effects of IAT and MT include in addition to those mentioned for IVT the 
risk of catheter angiography including iatrogenic thrombo-embolism and catheterization of the 
false lumen with rupture of the dissected artery. In 6 patients with sICAD who underwent IAT, 
no rupture of the dissected vessel, cervical, subarachnoid or intracranial hemorrhage, or peri-
interventional (Furlan et al 1999) arterial embolism was described (Abboud et al 2005; Arnold 
et al 2002; Sampognaro et al 1999; Zaidat et al 2001). Nedeltchev et al (Nedeltchev et al 2005) 
reported a patient with sICAD causing symptomatic occlusion of the middle cerebral artery who 
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underwent MT without adverse events. These limited data indicate that IAT and MT can be 
performed safely and successfully in selected patients with ischemic stroke due to sICAD.  
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